<DOC>
	<DOCNO>NCT01941407</DOCNO>
	<brief_summary>The efficacy eribulin well know metastatic breast cancer . Furthermore , phase III combine study ( chemo + bev ) metastatic first line show gain PFS extra toxicity . It could interest explore combination bev + eribulin first line metastatic breast cancer .</brief_summary>
	<brief_title>First Line Metastatic Breast Cancer Treatment ( ESMERALDA )</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>Age &gt; 18 an Patient metastatic mammary adenocarcinoma Hormone receptor ER PR positive negative HER 2 negative Prior chemotherapy metastatic disease Previous treatment eribulin bevacizumab Presence symptomatic brain metastasis meningeal</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>